October 13, 2010
The FDA has added opioid dependence as an indication for long-acting
naltrexone (Vivitrol), a once-monthly injectable.
The drug, already approved to treat alcohol dependence, joins the short list of pharmacologic treatments for opioid addiction, including methadone and buprenorphine.
"We are always happy to have another addition to our arsenal of addiction treatment," said Petros Levounis, MD, of St. Luke's and Roosevelt Hospitals in Manhattan.